File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Management of advanced stage intermediate grade non-Hodgkin's lymphomas

TitleManagement of advanced stage intermediate grade non-Hodgkin's lymphomas
Authors
Liang, RHSChiu, EKWChan, TKTodd, DLoke, SL
KeywordsAdvanced stage
Chemotherapy
Intermediate grade
Non‐Hodgkin's lymphoma
Issue Date1990
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1990, v. 8 n. 3, p. 147-154 How to Cite?
DOI: http://dx.doi.org/10.1002/hon.2900080306
AbstractThe treatment result of 271 cases of advanced stage intermediate grade lymphoma were reviewed. Ninety-four patients received CHOP chemotherapy, 45 BACOP and 17 m-BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease-free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m-BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.
Persistent Identifierhttp://hdl.handle.net/10722/161828
ISSN
0278-0232
2023 Impact Factor: 3.3
2023 SCImago Journal Rankings: 0.820

 

DC FieldValueLanguage
dc.contributor.authorLiang, RHSen_US
dc.contributor.authorChiu, EKWen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorLoke, SLen_US
dc.date.accessioned2012-09-05T05:15:20Z-
dc.date.available2012-09-05T05:15:20Z-
dc.date.issued1990en_US
dc.identifier.citationHematological Oncology, 1990, v. 8 n. 3, p. 147-154en_US
dc.identifier.issn0278-0232en_US
dc.identifier.urihttp://hdl.handle.net/10722/161828-
dc.description.abstractThe treatment result of 271 cases of advanced stage intermediate grade lymphoma were reviewed. Ninety-four patients received CHOP chemotherapy, 45 BACOP and 17 m-BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease-free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m-BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_US
dc.relation.ispartofHematological Oncologyen_US
dc.subjectAdvanced stage-
dc.subjectChemotherapy-
dc.subjectIntermediate grade-
dc.subjectNon‐Hodgkin's lymphoma-
dc.subject.meshAnalysis Of Varianceen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshBleomycin - Administration & Dosageen_US
dc.subject.meshCyclophosphamide - Administration & Dosageen_US
dc.subject.meshDoxorubicin - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshL-Lactate Dehydrogenase - Blooden_US
dc.subject.meshLeucovorin - Administration & Dosageen_US
dc.subject.meshLymphoma, Non-Hodgkin - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMethotrexate - Administration & Dosageen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrednisolone - Administration & Dosageen_US
dc.subject.meshPrednisone - Administration & Dosageen_US
dc.subject.meshPrognosisen_US
dc.subject.meshVincristine - Administration & Dosageen_US
dc.titleManagement of advanced stage intermediate grade non-Hodgkin's lymphomasen_US
dc.typeArticleen_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/hon.2900080306en_US
dc.identifier.pmid1695608-
dc.identifier.scopuseid_2-s2.0-0025170757en_US
dc.identifier.volume8en_US
dc.identifier.issue3en_US
dc.identifier.spage147en_US
dc.identifier.epage154en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US
dc.identifier.scopusauthoridChiu, EKW=24827833600en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridLoke, SL=7006559512en_US
dc.identifier.issnl0278-0232-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats